期刊文献+

消瘰丸基于PI3K/Akt/mTORC1通路对实验性甲状腺肿大鼠的干预机制 被引量:14

Intervention Mechanism of Xiaoluowan on Experimental Goiter Rats Based on PI3K/Akt/mTORC1 Pathway
原文传递
导出
摘要 目的:通过观察消瘰丸对实验性甲状腺肿大鼠磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)/哺乳动物雷帕霉素靶蛋白复合物1(m TORC1)通路的影响,探究其对实验性甲状腺肿大鼠的治疗效果。方法:购买60只5月龄SPF级SD大鼠,雌雄各半,其中10只作为正常组,其余大鼠灌服丙基硫氧嘧啶(PTU)溶液构建结节性甲状腺肿大鼠模型,建模成功后随机分为模型组、左甲状腺素钠片组、消瘰丸低、中、高剂量组各10只。左甲状腺素钠片组采用15μg·kg^(-1)的左甲状腺素钠片灌胃,消瘰丸低、中、高剂量组分别采用低剂量10 g·kg^(-1)、中剂量20 g·kg^(-1)、高剂量30 g·kg^(-1)消瘰丸灌胃,正常组、模型组采用等体积0.9%氯化钠溶液灌胃。干预4周后采用5%苯巴比妥做常规腹腔注射麻醉后处死,显微镜观察大鼠病理组织学、采用罗氏电化学发光免疫分析仪检测血清甲状腺激素水平、酶联免疫吸附测定法(ELISA)检测血清细胞生长因子、采用高效液相色谱仪检测神经递质、蛋白免疫印迹法(Western blot)检测PI3K/Akt/m TORC1信号通路蛋白表达量。结果:与正常组比较,模型组碱性成纤维生长因子(b FGF)、血管内皮生长因子(VEGF)、胰岛素样生长因子-1(IGF-1)、5-羟色胺(5-HT)、促甲状腺激素(TSH)水平、PI3K、Akt、m TORC1蛋白表达量升高,去甲肾上腺素(NE)、三碘甲腺原氨酸(T_(3))、四碘甲腺原氨酸(T_(4))、游离三碘甲状腺原氨酸(FT_(3))、游离甲状腺激素(FT_(4))水平降低(P<0.05);与模型组比较,左甲状腺素钠片组、消瘰丸低、中、高剂量组b FGF、VEGF、IGF-1、5-HT、TSH水平,PI3K、Akt、m TORC1蛋白表达量降低,NE、T_(3)、T_(4)、FT_(3)、FT_(4)水平升高(P<0.05);左甲状腺素钠片组比较,消瘰丸低、中、高剂量组b FGF、VEGF、IGF-1、5-HT、TSH水平,PI3K、Akt、m TORC1蛋白表达量降低,NE、T_(3)、T_(4)、FT_(3)、FT_(4)水平升高(P<0.05)。结论:消瘰丸可能作用于PI3K/Akt/m TORC1信号通路,发挥其治疗结节性甲状腺肿的作用,且表现为剂量依赖。 Objective:By observing the effect of Xiaoluowan on phosphatidylinositol 3-kinase(PI3K)/protein kinase B(Akt)/mammalian target of rapamycin complex 1(m TORC1)pathway in experimental goiter rats,this study aims to explore its therapeutic effect on experimental goiter rats.Method:Sixty 5-month-old SDrats of SPF grade were purchased,half males and half females,of which 10 were used as a normal group,and the remaining rats were administrated with propylthiouracil(PTU)solution to induce nodular goiter.After successful modeling,rats were randomly divided into a model group,levothyroxine sodium tablets group,Xiaoluowan low-dose group,medium-dose group,and high-dose group,ten rats each.The levothyroxine sodium tablets group was given 15μg·kg^(-1)levothyroxine sodium tablets by gavage.The Xiaoluowan low-,medium-,and high-dose groups were given(ig)Xiaoluowan low-dose(10 g·kg^(-1)),medium-dose(20 g·kg^(-1)),and high-dose(30 g·kg^(-1))Xiaoluowan,and the normal group and model group were administered(ig)with the same volume of 0.9%sodium chloride solution.Four weeks after the intervention,rats were sacrificed by routine intraperitoneal anesthesia using 5%phenobarbital.Subsequently,the histopathology was observed under a microscope,and serum thyroid hormone levels were measured using a Roche electrochemiluminescence immunoassay analyzer.Serum cytokines were detected by enzyme-linked immunosorbent assay(ELISA),and neurotransmitters were measured using a high-performance liquid chromatograph.The protein level of PI3K/Akt/m TORC1 pathway was determined by Western blot.Result:As compared with the normal group,the levels of basic fibroblast growth factor(b FGF),vascular endothelial growth factor(VEGF),insulin-like growth factor(IGF-1),5-hydroxytryptamine(5-HT),and thyroid stimulating hormone(TSH)were increased,and PI3K,Akt,and m TORC1 protein levels were up-regulated in the model group,while the levels of norepinephrine(NE),triiodothyronine(T_(3)),tetraiodothyronine(T_(4)),free triiodothyronine(FT_(3)),and free thyroid hormone(FT_(4))were decreased(P<0.05).Compared with the model group,the levothyroxine sodium tablets group,and Xiaoluowan low-,medium-,and high-dose groups exhibited reduced levels of b FGF,VEGF,IGF-1,5-HT,and TSH,and down-regulated PI3K,Akt,and m TORC1 protein levels,and increased NE,T_(3),T_(4),FT_(3),and FT_(4)levels(P<0.05).Conclusion:Xiaoluowan may act on the PI3K/Akt/m TORC1 signaling pathway to play its role in the treatment of nodular goiter,and it is dose-dependent.
作者 梁伟 孙禹 陈丽新 程伟 李文兰 LIANG Wei;SUN Yu;CHEN Li-xin;CHENG Wei;LI Wen-lan(School of Pharmacy,Harbin University of Commerce,Harbin 150076,China)
出处 《中国实验方剂学杂志》 CAS CSCD 北大核心 2022年第8期30-36,共7页 Chinese Journal of Experimental Traditional Medical Formulae
基金 黑龙江省博士后面上项目(LBH-Z19074) 哈尔滨市应用技术研究与开发项目(2017RAQXJ046)。
关键词 消瘰丸 结节性甲状腺肿 磷脂酰肌醇3-激酶(PI3K) 蛋白激酶B(Akt) 哺乳动物雷帕霉素靶蛋白复合物1(mTORC1) Xiaoluowan nodular goiter phosphatidylinositol 3-kinase protein kinase B mammalian target of rapamycin complex 1(mTORC1)
  • 相关文献

参考文献14

二级参考文献129

  • 1周晓眉.消瘰丸加减治疗乳腺增生58例[J].甘肃中医学院学报,2005,22(3):39-40. 被引量:3
  • 2伍丽萍,施秉银,郭丽英,徐利,兰玲,刘娟,张进安,旬利茹.在雌性小鼠制备Graves病动物模型[J].中华内分泌代谢杂志,2006,22(4):388-391. 被引量:15
  • 3陈娟,冉丕鑫.4-羟基壬烯醛在疾病发生机制方面的研究进展[J].国际呼吸杂志,2006,26(11):821-824. 被引量:11
  • 4中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:901
  • 5TAMURA M,KIMURA H,KOJI T,et al. Role of apoptosis of thy- rocytes in a rat model of goiter, A possible involvement of Fas sys- tem [ J ]. Endocrinology, 1998,139 (8) : 3646- 3653.
  • 6MEZOSI E, YAMAZAKI H,BRETZ J D, et al. Aberrant apoptosis in thyroid epithelial cells from goiter nodules[J]. Journal of Clini- cal Endocrinology and Metabohism, 2002,87 (9) : 4264-4272.
  • 7T OXICOIEOGICAL D D, pathological. Applications of proliferating cell nuclear antigen(PCNA), a novel endogenous marker for cell proliferation[ J]. Critical Red-Jews in Toxicology., 1993,23 (1) : 77.
  • 8VAN DIERENDONCK J H, WIJSMAN J H, KEIJZER R, et al. Cell-cycle-related staining patterns of anti-proliferating cell nucle- ar antigen monoclonal antibodies. Comparison with BrdUrd labeling and Ki-67 staining[J] .The American Journal of Pathology, 1991, 138(5) : 1165-1172.
  • 9KUSUNOKI T, NAKANO T, FUNASAKA K, et al. Proliferating cell nuclear antigen (PCNA) on human diseased thyroid cells[J]. Nippon Jibiinkoka Gakkai Kaiho, 1993,96(4) :651-658.
  • 10VELICK J,TTTLACH M,LOJDA Z,et al. Expression of the prolif- erating cell nuclear antigen (PCNA) in the rat thyroid gland after exposure to bromide[J]. Acta Histochemica, 1997,99(4):391.

共引文献116

同被引文献242

引证文献14

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部